IBRX Stock Declines Pre-Market — ImmunityBio Resubmits Anktiva Application To FDA With Additional Data
Synopsis
ImmunityBio stated that the application includes additional information requested by the FDA to support its supplemental BLA for papillary disease.
ImmunityBio Inc. (IBRX) on Monday announced that it has resubmitted the supplemental biologics license application (BLA) to the U.S. Food and Drug Administration for Anktiva.
ImmunityBio stated that the application includes additional information requested by the FDA to support its supplemental BLA for papillary disease.
ImmunityBio shares were down more than 5% in Monday’s pre-market trade. Retail sentiment on Stocktwits around the company trended in the ‘bearish’ territory at the time of writing.
Get updates to this developing story directly on Stocktwits.<
For updates and corrections, email newsroom[at]stocktwits[dot]com.<
Stay updated with all the latest Business News, including market trends, Share Market News, stock updates, taxation, IPOs, banking, finance, real estate, savings, and investments. Track daily Gold Price changes, updates on DA Hike, and the latest developments on the 8th Pay Commission. Get in-depth analysis, expert opinions, and real-time updates to make informed financial decisions. Download the Asianet News Official App from the Android Play Store and iPhone App Store to stay ahead in business.